Що сталося
NDTV Profit reported that Insilico Medicine’s rentosertib showed early signs of reducing predicted biological age in a reanalysis of a small Phase 2a trial. The drug’s molecular structure and protein target were designed using AI methods, but the trial was conducted for idiopathic pulmonary fibrosis rather than longevity.
NDTV Profit reported, citing findings published by Hong Kong-based biotech firm Insilico Medicine in Nature Biotechnology and coverage by The New York Times, that rentosertib was associated with lower predicted biological age. The drug was originally developed for idiopathic pulmonary fibrosis, a progressive lung-scarring disease, and was tested in 42 patients over 12 weeks in a Phase 2a trial.
According to NDTV Profit, Insilico later reanalyzed blood samples from that trial with AI-based aging clocks. These models estimate biological age and health risk from proteins in blood. Across six independent proteomic clocks, patients receiving the drug showed reductions of roughly 2.6 to 6.2 predicted years, with the strongest signal around the fourth week of treatment.
The report says both the drug’s molecular structure and its target, the protein TNIK, were generated using AI methods combining disease data with aging biology. The source does not establish that AI alone produced the clinical effect, and it does not provide enough information here to assess the trial’s statistical methods, randomization, or full safety results.
Деталі джерела: ndtvprofit.com ↗
Чому це важливо
The report describes a potentially important extension of AI-assisted drug discovery: using computationally designed medicines to affect biomarkers associated with aging. If replicated in larger, purpose-built studies, the approach could influence how researchers search for therapies that target aging-related biology. However, the evidence currently concerns predicted biological-age measures, not demonstrated longer life, improved overall health, or reversal of aging. NDTV Profit’s account has not been independently confirmed here.
The finding is consequential because it connects AI-designed drug discovery with a measurable human biomarker associated with aging, rather than limiting AI’s role to laboratory screening or disease-specific target selection. It may offer researchers another way to identify candidate therapies that affect aging-related processes.
The result remains a proof of concept, not evidence that the drug slows human aging. NDTV Profit emphasized that the aging signal came from a reanalysis of a trial designed for lung disease, involved a small and ill patient population, and used aging clocks whose ability to measure true biological aging or predict long-term health remains debated.
No access or price is documented because rentosertib is still investigational in the source account. The report says additional clinical trials and regulatory review would be required, including studies focused on healthy people.
Інтерактивний механізм: як він насправді працює
Дослідіть технологію, що лежить в основі цієї розробки, в інтерактивному режимі.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
Що дивитися далі
Further clinical testing will determine whether rentosertib changes validated health outcomes, benefits healthy people, and has an acceptable safety profile. Researchers will also need to establish whether the reported aging-clock changes persist beyond the 12-week trial and predict meaningful long-term outcomes.
Watch for larger, prospectively designed trials that treat aging or age-related disease as a primary objective rather than analyzing a secondary endpoint from a lung-disease study.
Researchers will need to test whether changes in proteomic aging-clock estimates are reproducible, durable, and linked to functional health outcomes. A lower predicted age alone does not demonstrate longer life or improved quality of life.
Regulatory status, participant eligibility, dosing, safety findings, and any future availability or pricing are not provided in the source and remain unknown.